Selectively nonselective kinase inhibition: striking the right balance.

Article Details

Citation
Copy to clipboard

Morphy R

Selectively nonselective kinase inhibition: striking the right balance.

J Med Chem. 2010 Feb 25;53(4):1413-37. doi: 10.1021/jm901132v.

PubMed ID
20166671 [ View in PubMed
]
Abstract

Not Available

DrugBank Data that Cites this Article

Binding Properties
DrugTargetPropertyMeasurementpHTemperature (°C)
BosutinibProto-oncogene tyrosine-protein kinase SrcIC 50 (nM)3.8N/AN/ADetails
BosutinibTyrosine-protein kinase ABL1IC 50 (nM)1.1N/AN/ADetails
DasatinibProto-oncogene tyrosine-protein kinase SrcIC 50 (nM)0.6N/AN/ADetails
DasatinibTyrosine-protein kinase ABL1IC 50 (nM)0.8N/AN/ADetails
DasatinibTyrosine-protein kinase LckIC 50 (nM)4N/AN/ADetails
ErlotinibEpidermal growth factor receptorIC 50 (nM)2N/AN/ADetails
GefitinibEpidermal growth factor receptorIC 50 (nM)1N/AN/ADetails
ImatinibTyrosine-protein kinase ABL1IC 50 (nM)1.1N/AN/ADetails
ImatinibTyrosine-protein kinase ABL1IC 50 (nM)658N/AN/ADetails
LapatinibEpidermal growth factor receptorIC 50 (nM)10N/AN/ADetails
LapatinibReceptor tyrosine-protein kinase erbB-2IC 50 (nM)10N/AN/ADetails
NilotinibTyrosine-protein kinase ABL1IC 50 (nM)38N/AN/ADetails
PP-121Proto-oncogene tyrosine-protein kinase SrcIC 50 (nM)14N/AN/ADetails
SorafenibPlatelet-derived growth factor receptor betaIC 50 (nM)57N/AN/ADetails
SorafenibRAF proto-oncogene serine/threonine-protein kinaseIC 50 (nM)6N/AN/ADetails
SorafenibVascular endothelial growth factor receptor 2IC 50 (nM)90N/AN/ADetails
SunitinibMacrophage colony-stimulating factor 1 receptorIC 50 (nM)35N/AN/ADetails
SunitinibPlatelet-derived growth factor receptor betaIC 50 (nM)55N/AN/ADetails
SunitinibReceptor-type tyrosine-protein kinase FLT3IC 50 (nM)21N/AN/ADetails
SunitinibVascular endothelial growth factor receptor 2IC 50 (nM)38N/AN/ADetails